Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca

Executive Summary

Pfizer, Gilead, Allergan, Valeant and AstraZeneca are among the pharma and biotech companies still to report their third-quarter results. After Merck, Bristol-Myers, Lilly, Amgen, Novartis, Sanofi and others revealed their July-to-September performance, Scrip takes a look at what to expect in the weeks ahead.

You may also be interested in...



Allergan’s Namesake Acquisition Looks Well-Timed As Established Brands Falter

Allergan’s net product revenue in the third quarter fell slightly below analyst consensus, but revenue from the company’s 2015 purchase of Botox, Restasis and other products softened declines for established products Namenda and Asacol.

Gilead Coming To The End Of HCV Road With Triple-Drug Regimen

Gilead reported an expected and continued sales decline in HCV – an area in which the company soon will be done with R&D, since unmet needs have been filled or will be soon by drug regimens from Gilead and its competitors. The company is hunting new assets, but taking a disciplined approach on price and quality.

‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study

Allergan will pay $200m to exercise its option to buy Motus Therapeutics (formerly Rhythm Health) after what the pharma described as a successful Phase IIb study for relamorelin in diabetic gastroparesis.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097528

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel